Effects and Mechanism Analysis of Combined Infusion by Levosimendan and Vasopressin on Acute Lung Injury in Rats Septic Shock

Cell Biochemistry and Biophysics

Volumn 70, Issue 3, 2014, Pages 1639-1645

  Wang, Xuebing ^a   Ma, Shaolin ^a   Liu, Yang ^a   Xu, Wei ^a   Li, Zhanxia ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute lung injury; Arginine vasopressin; Levosimendan; Sepsis

Indexed keywords

CARDIOVASCULAR AGENT; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; HYDRAZONE DERIVATIVE; NITROGEN OXIDE; NORADRENALIN; PYRIDAZINE DERIVATIVE; SIMENDAN; VASOPRESSIN DERIVATIVE;

ACUTE LUNG INJURY; ANIMAL; BLOOD GAS ANALYSIS; COMPLICATION; DISEASE MODEL; DRUG COMBINATION; FEMALE; LUNG; METABOLISM; PATHOLOGY; RAT; SEPTIC SHOCK;

ACUTE LUNG INJURY; ANIMALS; BLOOD GAS ANALYSIS; CARDIOVASCULAR AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HMGB1 PROTEIN; HYDRAZONES; LUNG; NITROGEN OXIDES; NOREPINEPHRINE; PYRIDAZINES; RATS; SHOCK, SEPTIC; VASOPRESSINS;

EID: 84939875421     PISSN: 10859195     EISSN: 15590283     Source Type: Journal    
DOI: 10.1007/s12013-014-0107-1     Document Type: Article

References (30)

1. Huebinger, R. M., et al. (2010). Association of mitochondrial allele 4216C with increased risk for sepsis-related organ dysfunction and shock after burn injury. Shock,33(1), 19–23.
2. Hariprashad, A., & Rizzolo, D. (2013). Acute respiratory distress syndrome: an overview for physician assistants. JAAPA,26(9), 23–28.
3. Patel, G. P., et al. (2010). Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock,33(4), 375–380.
4. Dellinger, R. P., et al. (2013). Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Medicine,39(2), 165–228.
5. Personett, H. A., et al. (2012). Predictors of prolonged vasopressin infusion for the treatment of septic shock. Journal of Critical Care, 27(3), 318 e7–12.
6. Rehberg, S., et al. (2009). Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock. Intensive Care Medicine,35(7), 1286–1296.
7. Leone, M., & Boyle, W. A. (2006). Decreased vasopressin responsiveness in vasodilatory septic shock-like conditions. Critical Care Medicine,34(4), 1126–1130.
8. Russell, J. A., & Walley, K. R. (2010). Vasopressin and its immune effects in septic shock. Journal of Innate Immunity,2(5), 446–460.
9. Westphal, M., et al. (2011). Cardiopulmonary effects of low-dose arginine vasopressin in ovine acute lung injury. Critical Care Medicine,39(2), 357–363.
10. Morelli, A., et al. (2006). Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: A pilot study. Critical Care Medicine,34(9), 2287–2293.
11. Yokoshiki, H., et al. (1997). Levosimendan, a novel Ca2 + sensitizer, activates the glibenclamide-sensitive K + channel in rat arterial myocytes. European Journal of Pharmacology,333(2–3), 249–259.
12. Scheiermann, P., et al. (2009). Effects of intravenous and inhaled levosimendan in severe rodent sepsis. Intensive Care Medicine,35(8), 1412–1419.
13. Paraskevaidis, I. A., Parissis, J. T., & Th Kremastinos, D. (2005). Anti-inflammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: A novel mechanism of drug-induced improvement in contractile performance of the failing heart. Current Medicinal Chemistry: Cardiovascular & Hematological Agents,3(3), 243–247.
14. Ji, M., et al. (2012). Effects of combined levosimendan and vasopressin on pulmonary function in porcine septic shock. Inflammation,35(3), 871–880.
15. Perl, M., et al. (2007). Fas-induced pulmonary apoptosis and inflammation during indirect acute lung injury. American Journal of Respiratory and Critical Care Medicine,176(6), 591–601.
16. De Paepe, M. E., et al. (2005). Hyperoxia-induced apoptosis and Fas/FasL expression in lung epithelial cells. American Journal of Physiology. Lung Cellular and Molecular Physiology,289(4), L647–L659.
17. Gloor, B., et al. (2000). Kupffer cell blockade reduces hepatic and systemic cytokine levels and lung injury in hemorrhagic pancreatitis in rats. Pancreas,21(4), 414–420.
18. Zou, J. Y., & Crews, F. T. (2014). Release of neuronal HMGB1 by ethanol through decreased HDAC activity activates brain neuroimmune signaling. PLoS ONE,9(2), e87915.
19. Asfar, P., et al. (2003). Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Critical Care Medicine,31(1), 215–220.
20. Garcia-Septien, J., et al. (2010). Levosimendan increases portal blood flow and attenuates intestinal intramucosal acidosis in experimental septic shock. Shock,34(3), 275–280.
21. Li, W., et al. (2013). Novel insights into phosgene-induced acute lung injury in rats: role of dysregulated cardiopulmonary reflexes and nitric oxide in lung edema pathogenesis. Toxicological Sciences,131(2), 612–628.
22. Shih, H. C., Huang, M. S., & Lee, C. H. (2012). Magnolol attenuates the lung injury in hypertonic saline treatment from mesenteric ischemia reperfusion through diminishing iNOS. Journal of Surgical Research,175(2), 305–311.
23. Sareila, O., et al. (2008). Effects of levo- and dextrosimendan on NF-kappaB-mediated transcription, iNOS expression and NO production in response to inflammatory stimuli. British Journal of Pharmacology,155(6), 884–895.
24. Umino, T., et al. (1999). AVP inhibits LPS- and IL-1beta-stimulated NO and cGMP via V1 receptor in cultured rat mesangial cells. American Journal of Physiology,276(3 Pt 2), F433–F441.
25. Ware, L. B., et al. (2010). Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest,137(2), 288–296.
26. Feroze, U., et al. (2012). Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. Journal of Renal Nutrition,22(3), 317–326.
27. Echtenacher, B., Mannel, D. N., & Hultner, L. (1996). Critical protective role of mast cells in a model of acute septic peritonitis. Nature,381(6577), 75–77.
28. Lee, W., et al. (2014). Anti-septic effects of glyceollins in HMGB1-induced inflammatory responses in vitro and in vivo. Food and Chemical Toxicology,63, 1–8.
29. Gentile, L. F., & Moldawer, L. L. (2014). HMGB1 as a therapeutic target for sepsis: It’s all in the timing! Expert Opinion on Therapeutic Targets,18(3), 243–245.
30. Wolfson, R. K., Chiang, E. T., & Garcia, J. G. (2011). HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption. Microvascular Research,81(2), 189–197.